Hey Stayso
Genentech doesn’t have to worry about any capital requirements with gdc0084
imo
Milestone payment due on phase 11b without worrying about the $20m or so estimated cost and also hasn’t any dilution concerns etc
research developing own drugs vs those purchased on licence agreements
dyor
- Forums
- ASX - By Stock
- KZA
- Ann: WHO selects provisional name for Kazia's GDC-0084
Ann: WHO selects provisional name for Kazia's GDC-0084, page-13
-
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)